"Sarcoidosis, Pulmonary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sarcoidosis affecting predominantly the lungs, the site most frequently involved and most commonly causing morbidity and mortality in sarcoidosis. Pulmonary sarcoidosis is characterized by sharply circumscribed granulomas in the alveolar, bronchial, and vascular walls, composed of tightly packed cells derived from the mononuclear phagocyte system. The clinical symptoms when present are dyspnea upon exertion, nonproductive cough, and wheezing. (Cecil Textbook of Medicine, 19th ed, p431)
Descriptor ID |
D017565
|
MeSH Number(s) |
C08.381.483.725 C15.604.515.827.725
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sarcoidosis, Pulmonary".
Below are MeSH descriptors whose meaning is more specific than "Sarcoidosis, Pulmonary".
This graph shows the total number of publications written about "Sarcoidosis, Pulmonary" by people in this website by year, and whether "Sarcoidosis, Pulmonary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 2 | 0 | 2 |
2004 | 1 | 0 | 1 |
2006 | 3 | 0 | 3 |
2007 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sarcoidosis, Pulmonary" by people in Profiles.
-
Loza MJ, Brodmerkel C, Du Bois RM, Judson MA, Costabel U, Drent M, Kavuru M, Flavin S, Lo KH, Barnathan ES, Baughman RP. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol. 2011 Jun; 18(6):931-9.
-
Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S, Lo KH, Barnathan ES. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009 Aug; 136(2):526-35.
-
Vahid B, Weibel S. Glioblastoma multiforme disguised as sarcoidosis: pitfalls in diagnosis. South Med J. 2007 Mar; 100(3):335.
-
Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Müller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006 Oct 1; 174(7):795-802.
-
Barna BP, Culver DA, Abraham S, Malur A, Bonfield TL, John N, Farver CF, Drazba JA, Raychaudhuri B, Kavuru MS, Thomassen MJ. Depressed peroxisome proliferator-activated receptor gamma (PPargamma) is indicative of severe pulmonary sarcoidosis: possible involvement of interferon gamma (IFN-gamma). Sarcoidosis Vasc Diffuse Lung Dis. 2006 Jun; 23(2):93-100.
-
Perez RL, Kimani AP, King TE, Aguayo SM, Roman J. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration. 2007; 74(3):297-303.
-
Culver DA, Thomassen MJ, Kavuru MS. Pulmonary sarcoidosis: new genetic clues and ongoing treatment controversies. Cleve Clin J Med. 2004 Feb; 71(2):88, 90, 92 passim.
-
Culver DA, Barna BP, Raychaudhuri B, Bonfield TL, Abraham S, Malur A, Farver CF, Kavuru MS, Thomassen MJ. Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2004 Jan; 30(1):1-5.
-
Perez RL, Rivera-Marrero CA, Roman J. Pulmonary granulomatous inflammation: From sarcoidosis to tuberculosis. Semin Respir Infect. 2003 Mar; 18(1):23-32.